Media, page-122

Excellent find @bigjez. A good synopsis from Fred.

Here's another recent research paper from Kuick Research that focuses only on anti-Lag3. The relevance is imminent BMS - Relatlimab FDA approval (hopefully) 19th March 2022, which would unequivocally validate Lag-3 as the third ICI pillar :-

The Development of LAG3 Inhibitors To Give New Paradigm Shift to Cancer Immunotherapy Market says KuicK Research

The LAG-3 inhibitor market is expected to exhibit significant market growth during the forecast period, owing to growth in demand for ideal therapeutics for treatment of cancer, favourable reimbursement policies provided by manufacturers and insurance providers in some countries, and surge in prevalence of cancer across the globe.
The key factors driving growth of LAG-3 inhibitor market growth are attributed to increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for treatment of cancer, higher number of research and development studies, and surge in adoption of immune checkpoint inhibitor drugs.
In addition, growth in geriatric population and technological advancements in screening and diagnosis of cancer further drives the market growth. As per our report findings, the global LAG-3 inhibitor market is expected to surpass US$ 2 Billion by 2028. The report helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analysing the market, unmet needs, drivers and barriers, and demand for better technology.